SPRI is pleased to announce that we are now part of the Accelerated Clinical Trial Agreement program (ACTA). This allows us to significantly reduce contract negotiation time and get your project up and running faster.
150th subject (75% complete) enrolled in the Advanced Parkinson’s Post Marketing Study as of 07 July. On schedule to meet enrollment by the end of 2017. Congratulations to the 52 active sites across 10 countries!
Enrollment completed for all cohorts in a Proof of Concept Open-label, Dose-Escalation Study in subjects with Mild to Moderate Ulcerative Proctitis (UP) or Ulcerative Proctosigmoiditis (UPS). Congratulations to our Georgian sites!
EASL (Amsterdam 2017). Exciting to see the series of LOWR abstracts at EASL highlighting the Hepatitis Delta studies with Lonafarnib. SPRI clinical has enjoyed the great partnership with the sites in advancing the understanding of Hepatitis Delta.